$CYTH
Cyclo Therapeutics, Inc. Stock $cyth

$cyth Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924017038 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$123.1K	$202.5K
YoY Change	5.11%	32.83%
Cost Of Revenue	$21.35K	$14.19K
YoY Change	-20.84%	23.93%
Gross Profit	$109.7K	$190.6K
YoY Change	21.71%	35.23%
Gross Profit Margin	89.13%	94.16%
Selling, General & Admin	$2.243M	$2.450M
YoY Change	44.92%	40.38%
% of Gross Profit	2044.67%	1285.15%
Research & Development	$3.492M	$2.845M
YoY Change	10.14%	-16.26%
% of Gross Profit	3182.38%	1492.7%
Depreciation & Amortization	$2.170K	$2.177K
YoY Change	-54.98%	-54.82%
% of Gross Profit	1.98%	1.14%
Operating Expenses	$3.492M	$2.845M
YoY Change	10.14%	-16.26%
Operating Profit	-$5.636M	-$5.121M
YoY Change	21.64%	2.28%
Interest Expense	-$195.9K	$237.6K
YoY Change	5480.63%	475040.0%
% of Operating Profit
Other Income/Expense, Net	-$345.6K	$778.0K
YoY Change	9736.69%	1655217.02%
Pretax Income	-$5.981M	-$4.343M
YoY Change	29.0%	-13.26%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.981M	-$4.343M
YoY Change	29.0%	-13.26%
Net Earnings / Revenue	-4858.7%	-2145.25%
Basic Earnings Per Share	-$0.21	-$0.15
Diluted Earnings Per Share	-$0.21	-$0.15
COMMON SHARES
Basic Shares Outstanding	28.62M	28.72M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.122M	$2.995M
YoY Change	33.31%	227.28%
Cash & Equivalents	$1.122M	$2.995M
Short-Term Investments
Other Short-Term Assets	$3.004M	$3.261M
YoY Change	-11.17%	20.66%
Inventory	$241.0K	$242.5K
Prepaid Expenses
Receivables	$83.74K	$71.32K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$4.450M	$6.570M
YoY Change	-2.14%	64.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$22.17K	$24.34K
YoY Change	-51.34%	-51.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$267.7K	$593.8K
YoY Change	182.71%	472.29%
TOTAL ASSETS
Total Short-Term Assets	$4.450M	$6.570M
Total Long-Term Assets	$267.7K	$593.8K
Total Assets	$4.718M	$7.164M
YoY Change	1.63%	74.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.860M	$3.671M
YoY Change	-36.5%	-18.11%
Accrued Expenses	$1.577M	$1.746M
YoY Change	8927.36%	10187.8%
Deferred Revenue
YoY Change
Short-Term Debt	$2.711M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.829M	$6.536M
YoY Change	61.24%	45.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$12.38K	$17.51K
YoY Change	-61.24%	-52.07%
Total Long-Term Liabilities	$12.38K	$17.51K
YoY Change	-61.25%	-52.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.829M	$6.536M
Total Long-Term Liabilities	$12.38K	$17.51K
Total Liabilities	$9.841M	$6.554M
YoY Change	60.6%	44.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$94.18M	-$88.20M
YoY Change	28.24%	28.19%
Common Stock	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.123M	$610.0K
YoY Change
Total Liabilities & Shareholders Equity	$4.718M	$7.164M
YoY Change	1.63%	74.85%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$5.981M	-$4.343M
YoY Change	29.0%	-13.26%
Depreciation, Depletion And Amortization	$2.170K	$2.177K
YoY Change	-54.98%	-54.82%
Cash From Operating Activities	-$3.848M	-$6.182M
YoY Change	10.62%	41.46%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.975M	-$69.28K
YoY Change	-42.0%	-101.85%
NET CHANGE
Cash From Operating Activities	-3.848M	-$6.182M
Cash From Investing Activities
Cash From Financing Activities	1.975M	-$69.28K
Net Change In Cash	-1.873M	-$6.251M
YoY Change	2443.61%	895.06%
FREE CASH FLOW
Cash From Operating Activities	-$3.848M	-$6.182M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9246592	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17507	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	17507	usd
CY2024Q1	us-gaap	Salaries And Wages SalariesAndWages	822481	usd
CY2023Q1	us-gaap	Salaries And Wages SalariesAndWages	906955	usd
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2995000	usd
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000922247
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2995000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6182000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88200000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4343000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	10272	usd
CY2023Q4	us-gaap	Assets Assets	13247538	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1010631	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5888813	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6536369	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28614384
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28614384
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28556072
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28556072
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	2862	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	2856	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88806896	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88610832	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88199744	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83856681	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	610014	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4757007	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7163890	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13247538	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	202450	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	152411	usd
CY2024Q1	ctdh	Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts	11823	usd
CY2023Q1	ctdh	Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts	10196	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	190627	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	142215	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2845483	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3398167	usd
CY2024Q1	ctdh	Repairs And Maintenance RepairsAndMaintenance	2363	usd
CY2023Q1	ctdh	Repairs And Maintenance RepairsAndMaintenance	1252	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	630388	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	482835	usd
CY2024Q1	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	892213	usd
CY2023Q1	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	282375	usd
CY2024Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	104398	usd
CY2023Q1	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	72125	usd
CY2024Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	2177	usd
CY2023Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	4819	usd
CY2024Q1	ctdh	Freight And Shipping FreightAndShipping	373	usd
CY2023Q1	ctdh	Freight And Shipping FreightAndShipping	819	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-11813	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	5311689	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	5149347	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5121062	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5007132	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	237568	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	47	usd
CY2024Q1	us-gaap	Lease Income LeaseIncome	540431	usd
CY2023Q1	us-gaap	Lease Income LeaseIncome	0	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	777999	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	47	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4343063	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5007085	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4343063	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5007085	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28585228
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11003588
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4757007	usd
CY2024Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	69281	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	173218	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4343063	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	610014	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	734544	usd
CY2023Q1	ctdh	Stock Issued During Period Value Common Stock And Prefunded Warrants StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrants	3741883	usd
CY2023Q1	ctdh	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	114	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	91668	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5007085	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-438876	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4343063	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5007085	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2177	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4819	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-11813	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	173218	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	91668	usd
CY2024Q1	ctdh	Sharebased Compensation Nonemployees SharebasedCompensationNonemployees	92133	usd
CY2023Q1	ctdh	Sharebased Compensation Nonemployees SharebasedCompensationNonemployees	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-51057	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	76233	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-11822	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-9994	usd
CY2024Q1	ctdh	Increase Decrease Prepaid Clinical Expenses IncreaseDecreasePrepaidClinicalExpenses	508159	usd
CY2023Q1	ctdh	Increase Decrease Prepaid Clinical Expenses IncreaseDecreasePrepaidClinicalExpenses	309403	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Insurance IncreaseDecreaseInPrepaidInsurance	104528	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Insurance IncreaseDecreaseInPrepaidInsurance	87503	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-0	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1573	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1568603	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1001931	usd
CY2024Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-1839070	usd
CY2023Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	636846	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6182133	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4370239	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2407849	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1334034	usd
CY2024Q1	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	69281	usd
CY2023Q1	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	-0	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	114	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-69281	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3741997	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6251414	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-628242	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9246592	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1543418	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2995178	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	915176	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	756	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1730	usd
CY2024Q1	ctdh	Working Capital Deficit WorkingCapitalDeficit	34000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	10000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	202450	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	152411	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3670646	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4856530	usd
CY2024Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	996161	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1590776	usd
CY2024Q1	ctdh	Accrued Board Expense Current AccruedBoardExpenseCurrent	102125	usd
CY2023Q4	ctdh	Accrued Board Expense Current AccruedBoardExpenseCurrent	92110	usd
CY2024Q1	us-gaap	Deposit Liability Current DepositLiabilityCurrent	243742	usd
CY2023Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	243742	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	487342	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	487402	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	388797	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	186856	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5888813	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7457416	usd
CY2024Q1	ctdh	Operating Lease Right Of Usse Asset Amortization OperatingLeaseRightOfUsseAssetAmortization	321472	usd
CY2023Q4	ctdh	Operating Lease Right Of Usse Asset Amortization OperatingLeaseRightOfUsseAssetAmortization	17242	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	527417	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	9535	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4343063	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5007085	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	28585228
CY2023Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	11003588
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2024Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	980000	usd

Files In Submission

Name	View Source	Status
0001437749-24-017038-index-headers.html	Edgar Link	pending
0001437749-24-017038-index.html	Edgar Link	pending
0001437749-24-017038.txt	Edgar Link	pending
0001437749-24-017038-xbrl.zip	Edgar Link	pending
ctdh-20240331.xsd	Edgar Link	pending
ctdh20240331_10q.htm	Edgar Link	pending
ex_670355.htm	Edgar Link	pending
ex_670356.htm	Edgar Link	pending
ex_670357.htm	Edgar Link	pending
ex_670358.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
ctdh-20240331_def.xml	Edgar Link	unprocessable
ctdh-20240331_lab.xml	Edgar Link	unprocessable
ctdh-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ctdh20240331_10q_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ctdh-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYTH
Cyclo Therapeutics, Inc. Stock $cyth

2024 Q2 Form 10-Q Financial Statement

#000143774924017038 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYTH Cyclo Therapeutics, Inc. Stock $cyth

2024 Q2 Form 10-Q Financial Statement

#000143774924017038 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYTH
Cyclo Therapeutics, Inc. Stock $cyth